Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy

OBJECTIVE: A minority of HIV-1 positive individuals treated with antiretroviral therapy (ART) in primary HIV-1 infection (PHI) maintain viral suppression on stopping. Whether this is related to ART duration has not been explored. DESIGN: And Methods: Using SPARTAC trial data from individuals recruit...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Stöhr, W, Fidler, S, McClure, M, Weber, J, Cooper, D, Ramjee, G, Kaleebu, P, Tambussi, G, Schechter, M, Babiker, A, Phillips, R, Porter, K, Frater, J
Formato:	Journal article
Idioma:	English
Publicado em:	Public Library of Science 2013

Registos relacionados

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.
Por: Wolfgang Stöhr, et al.
Publicado em: (2013-01-01)

Short-course antiretroviral therapy in primary HIV infection.
Por: Fidler, S, et al.
Publicado em: (2013)

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection
Por: Hamlyn, E, et al.
Publicado em: (2012)

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
Por: Gossez, M, et al.
Publicado em: (2018)

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.
Por: Elizabeth Hamlyn, et al.
Publicado em: (2012-01-01)

Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial
Por: Jasmini Alagaratnam, et al.
Publicado em: (2024-06-01)

Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy.
Por: Frater, A, et al.
Publicado em: (2002)

Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients.
Por: Frater, A, et al.
Publicado em: (2001)

Protective HLA class I alleles are associated with reduced immune activation and fibrinolysis in individuals with primary HIV infection
Por: Hamlyn, E, et al.
Publicado em: (2010)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
Por: Fidler, S, et al.
Publicado em: (2002)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
Por: Fidler, S, et al.
Publicado em: (2002)

HIV-1 DNA predicts disease progression and post-treatment virological control.
Por: Williams, J, et al.
Publicado em: (2014)

4 Post-treatment control or treated controllers? The impact of ART on time to viral rebound in recent seroconverters
Por: G.E. Martin, et al.
Publicado em: (2016-07-01)

Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.
Por: Fidler, S, et al.
Publicado em: (2007)

Early antiretroviral therapy reduces hiv dna following perinatal HIV infection
Por: Foster, C, et al.
Publicado em: (2017)

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial
Por: Fidler, S, et al.
Publicado em: (2020)

Extended-duration transdermal nicotine therapy was more effective than standard-duration therapy for smoking cessation.
Por: Lancaster, T, et al.
Publicado em: (2010)

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound
Por: P. Zacharopoulou, et al.
Publicado em: (2022-01-01)

TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
Por: Angus, B, et al.
Publicado em: (2008)

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions
Por: Jakub Kopycinski, et al.
Publicado em: (2023-10-01)

HIV-1 resistance genotyping by sequencing produces inconsistent results for mixed viral populations.
Por: Frater, A, et al.
Publicado em: (2000)

Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis.
Por: Claudia P Cortes, et al.
Publicado em: (2013-01-01)

HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper
Por: S. Fidler, et al.
Publicado em: (2021-03-01)

Individualization of antiretroviral therapy
Por: Pavlos R, et al.
Publicado em: (2011-12-01)

How soon after HIV seroconversion is antiretroviral therapy initiated?
Por: Babiker, A, et al.
Publicado em: (1999)

Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.
Por: Hamlyn, E, et al.
Publicado em: (2012)

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation
Por: Theodoulou, A, et al.
Publicado em: (2023)

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation (Review)
Por: Lindson, N, et al.
Publicado em: (2019)

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
Por: Hurst, J, et al.
Publicado em: (2015)

Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.
Por: English, S, et al.
Publicado em: (2011)

Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption
Por: Matthew Pace, et al.
Publicado em: (2022-08-01)

A randomised controlled trial comparing the impact of Antiretroviral Therapy (ART) with a ‘Kick-and-Kill’ approach to ART alone on HIV reservoirs in individuals with primary HIV infection (PHI); RIVER trial
Por: Fidler, S, et al.
Publicado em: (2018)

Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome.
Por: Frater, J, et al.
Publicado em: (2002)

HIV-1 Specific CD4 Responses in Primary HIV-1 Infection predict disease progression in the SPARTAC Trial
Por: Frater, A, et al.
Publicado em: (2013)

THE INFLUENCE OF HIV INFECTION DURATION BEFORE ANTIRETROVIRAL THERAPY ON IMMUNOLOGICAL TREATMENT FAILURE
Por: A. F. Oleynik, et al.
Publicado em: (2017-06-01)

Integrating antiretroviral therapy into antenatal care and maternal and child health settings: a systematic review and meta-analysis
Por: Amitabh B Suthar, et al.
Publicado em: (2013-01-01)

Nicontine replacement therapy for smoking cessation
Por: Silagy, G, et al.
Publicado em: (2005)

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.
Por: Le, T, et al.
Publicado em: (2011)

Smoking Cessation Therapy
Por: Nurhidayati Fawzani, et al.
Publicado em: (2010-10-01)

Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration
Por: Nishida Yasuharu, et al.
Publicado em: (2011-05-01)